Inhibin subunit beta B (INHBB): an emerging role in tumor progression.
Activin
Cancer
INHBB
Inhibin
Tumor progression
Journal
Journal of physiology and biochemistry
ISSN: 1877-8755
Titre abrégé: J Physiol Biochem
Pays: Spain
ID NLM: 9812509
Informations de publication
Date de publication:
26 Aug 2024
26 Aug 2024
Historique:
received:
20
09
2023
accepted:
30
07
2024
medline:
26
8
2024
pubmed:
26
8
2024
entrez:
25
8
2024
Statut:
aheadofprint
Résumé
The gene inhibin subunit beta B (INHBB) encodes the inhibin βB subunit, which is involved in forming protein members of the transforming growth factor-β (TGF-β) superfamily. The TGF-β superfamily is extensively involved in cell proliferation, differentiation, adhesion, movement, metabolism, communication, and death. Activins and inhibins, which belong to the TGF-β superfamily, were first discovered in ovarian follicular fluid. They were initially described as regulators of pituitary follicle-stimulating hormone (FSH) secretion both in vivo and in vitro. Later studies found that INHBB is expressed not only in reproductive organs such as the ovary, uterus, and testis but also in numerous other organs, including the brain, spinal cord, liver, kidneys, and adrenal glands. This wide distribution implies its involvement in the normal physiological functions of various organs; however, the mechanisms underlying these functions have not yet been fully elucidated. Recent studies suggest that INHBB plays a significant, yet complex role in tumorigenesis. It appears to have dual effects, promoting tumor progression in some contexts while inhibiting it in others, although these roles are not yet fully understood. In this paper, we review the different expression patterns, functions, and mechanisms of INHBB in normal and tumor tissues to illustrate the research prospects of INHBB in tumor progression.
Identifiants
pubmed: 39183219
doi: 10.1007/s13105-024-01041-y
pii: 10.1007/s13105-024-01041-y
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : the Natural Science Foundation of Hunan Province, China
ID : 2020JJ4780
Organisme : National Natural Science Foundation of China
ID : 81672688
Informations de copyright
© 2024. The Author(s) under exclusive licence to University of Navarra.
Références
Abushahba W, Olabisi OO, Jeong BS, Boregowda RK, Wen Y, Liu F, Goydos JS, Lasfar A, Cohen-Solal KA (2012) Non-canonical smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanoma. PLoS ONE 7:e47312. https://doi.org/10.1371/journal.pone.0047312
doi: 10.1371/journal.pone.0047312
pubmed: 23077590
pmcid: 3470581
Adkins HB, Bianco C, Schiffer SG, Rayhorn P, Zafari M, Cheung AE, Orozco O, Olson D, De Luca A, Chen LL, Miatkowski K, Benjamin C, Normanno N, Williams KP, Jarpe M, LePage D, Salomon D, Sanicola M (2003) Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest 112:575–587. https://doi.org/10.1172/jci17788
doi: 10.1172/jci17788
pubmed: 12925698
pmcid: 171388
Afrakhte M, Morén A, Jossan S, Itoh S, Sampath K, Westermark B, Heldin CH, Heldin NE, ten Dijke P (1998) Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. Biochem Biophys Res Commun 249:505–511. https://doi.org/10.1006/bbrc.1998.9170
doi: 10.1006/bbrc.1998.9170
pubmed: 9712726
Anderson RA, Cambray N, Hartley PS, McNeilly AS (2002) Expression and localization of inhibin alpha, inhibin/activin betaA and betaB and the activin type II and inhibin beta-glycan receptors in the developing human testis. Reproduction 123:779–788. https://doi.org/10.1530/rep.0.1230779
doi: 10.1530/rep.0.1230779
pubmed: 12052232
Appiah Adu-Gyamfi E, Tanam Djankpa F, Nelson W, Czika A, Kumar Sah S, Lamptey J, Ding YB, Wang YX (2020) Activin and inhibin signaling: from regulation of physiology to involvement in the pathology of the female reproductive system. Cytokine 133:155105. https://doi.org/10.1016/j.cyto.2020.155105
doi: 10.1016/j.cyto.2020.155105
pubmed: 32438278
Bao H, Sin TK, Zhang G (2020) Activin A induces tumorigenesis of leiomyoma via regulation of p38β MAPK-mediated signal cascade. Biochem Biophys Res Commun 529:379–385. https://doi.org/10.1016/j.bbrc.2020.05.079
doi: 10.1016/j.bbrc.2020.05.079
pubmed: 32703439
Batlle E, Massagué J (2019) Transforming growth Factor-β signaling in immunity and Cancer. Immunity 50:924–940. https://doi.org/10.1016/j.immuni.2019.03.024
doi: 10.1016/j.immuni.2019.03.024
pubmed: 30995507
pmcid: 7507121
Bernard DJ (2004) Both SMAD2 and SMAD3 mediate activin-stimulated expression of the follicle-stimulating hormone beta subunit in mouse gonadotrope cells. Mol Endocrinol 18:606–623. https://doi.org/10.1210/me.2003-0264
doi: 10.1210/me.2003-0264
pubmed: 14701940
Bernard DJ, Lee KB, Santos MM (2006) Activin B can signal through both ALK4 and ALK7 in gonadotrope cells. Reprod Biol Endocrinol 4:52. https://doi.org/10.1186/1477-7827-4-52
doi: 10.1186/1477-7827-4-52
pubmed: 17040568
pmcid: 1617107
Bildik G, Akin N, Esmaeilian Y, Hela F, Yildiz CS, Iltumur E, İncir S, Karahuseyinoglu S, Yakin K, Oktem O (2020) Terminal differentiation of human granulosa cells as luteinization is reversed by activin-A through silencing of Jnk pathway. Cell Death Discov 6:93. https://doi.org/10.1038/s41420-020-00324-9
doi: 10.1038/s41420-020-00324-9
pubmed: 33042587
pmcid: 7511402
Bilezikjian LM, Blount AL, Campen CA, Gonzalez-Manchon C, Vale W (1991) Activin-A inhibits proopiomelanocortin messenger RNA accumulation and adrenocorticotropin secretion of AtT20 cells. Mol Endocrinol 5:1389–1395. https://doi.org/10.1210/mend-5-10-1389
doi: 10.1210/mend-5-10-1389
pubmed: 1663577
Bilezikjian LM, Corrigan AZ, Blount AL, Chen Y, Vale WW (2001) Regulation and actions of Smad7 in the modulation of activin, inhibin, and transforming growth factor-beta signaling in anterior pituitary cells. Endocrinology 142:1065–1072. https://doi.org/10.1210/endo.142.3.8028
doi: 10.1210/endo.142.3.8028
pubmed: 11181520
Bloise E, Ciarmela P, Dela Cruz C, Luisi S, Petraglia F, Reis FM (2019) Activin A in mammalian physiology. Physiol Rev 99:739–780. https://doi.org/10.1152/physrev.00002.2018
doi: 10.1152/physrev.00002.2018
pubmed: 30540228
Brand JS, Humphreys K, Li J, Karlsson R, Hall P, Czene K (2018) Common genetic variation and novel loci associated with volumetric mammographic density. Breast Cancer Res 20:30. https://doi.org/10.1186/s13058-018-0954-6
doi: 10.1186/s13058-018-0954-6
pubmed: 29665850
pmcid: 5904990
Burdette JE, Woodruff TK (2007) Activin and estrogen crosstalk regulates transcription in human breast cancer cells. Endocr Relat Cancer 14:679–689. https://doi.org/10.1677/erc-07-0054
doi: 10.1677/erc-07-0054
pubmed: 17914098
Burger HG, Baillie A, Drummond AE, Healy DL, Jobling T, Mamers P, Robertson DM, Susil B, Cahir N, Shen Y, Verity K, Fuller PJ, Groome NP, Findlay JK (1998) Inhibin and ovarian cancer. J Reprod Immunol 39:77–87. https://doi.org/10.1016/s0165-0378(98)00014-x
doi: 10.1016/s0165-0378(98)00014-x
pubmed: 9786454
Burges A, Shabani N, Brüning A, Mylonas I (2011) Inhibin-Betaa and -betab subunits in normal and malignant glandular epithelium of uterine cervix and HeLa cervical cancer cell line. Arch Gynecol Obstet 284:981–988. https://doi.org/10.1007/s00404-010-1734-4
doi: 10.1007/s00404-010-1734-4
pubmed: 21082187
Canali S, Core AB, Zumbrennen-Bullough KB, Merkulova M, Wang CY, Schneyer AL, Pietrangelo A, Babitt JL (2016) Activin B induces noncanonical SMAD1/5/8 signaling via BMP type I receptors in hepatocytes: evidence for a role in Hepcidin Induction by inflammation in male mice. Endocrinology 157:1146–1162. https://doi.org/10.1210/en.2015-1747
doi: 10.1210/en.2015-1747
pubmed: 26735394
pmcid: 4769363
Cangkrama M, Wietecha M, Werner S (2020) Wound repair, scar formation, and Cancer: converging on activin. Trends Mol Med 26:1107–1117. https://doi.org/10.1016/j.molmed.2020.07.009
doi: 10.1016/j.molmed.2020.07.009
pubmed: 32878730
Chen Y, Qian B, Sun X, Kang Z, Huang Z, Ding Z, Dong L, Chen J, Zhang J, Zang Y (2021) Sox9/INHBB axis-mediated crosstalk between the hepatoma and hepatic stellate cells promotes the metastasis of hepatocellular carcinoma. Cancer Lett 499:243–254. https://doi.org/10.1016/j.canlet.2020.11.025
doi: 10.1016/j.canlet.2020.11.025
pubmed: 33246092
Chen X, Zhao C, Xu Y, Huang K, Wang Y, Wang X, Zhou X, Pang W, Yang G, Yu T (2021) Adipose-specific BMP and activin membrane-bound inhibitor (BAMBI) deletion promotes adipogenesis by accelerating ROS production. J Biol Chem 296:100037. https://doi.org/10.1074/jbc.RA120.014793
doi: 10.1074/jbc.RA120.014793
pubmed: 33158991
Cobellis L, Cataldi P, Reis FM, De Palo G, Raspagliesi F, Pilotti S, Arcuri F, Petraglia F (2001) Gonadal malignant germ cell tumors express immunoreactive inhibin/activin subunits. Eur J Endocrinol 145:779–784. https://doi.org/10.1530/eje.0.1450779
doi: 10.1530/eje.0.1450779
pubmed: 11720904
De Jong FH (1988) Inhibin. Physiol Rev 68:555–607. https://doi.org/10.1152/physrev.1988.68.2.555
doi: 10.1152/physrev.1988.68.2.555
pubmed: 3282246
Deng SK, Tang JZ, Jin Y, Hu PH, Wang JF, Zhang XW (2020) Activin B signaling may promote the conversion of normal fibroblasts to scar fibroblasts. Med (Baltim) 99:e20253. https://doi.org/10.1097/md.0000000000020253
doi: 10.1097/md.0000000000020253
Derynck R, Turley SJ, Akhurst RJ (2021) TGFβ biology in cancer progression and immunotherapy. Nat Rev Clin Oncol 18:9–34. https://doi.org/10.1038/s41571-020-0403-1
doi: 10.1038/s41571-020-0403-1
pubmed: 32710082
Devaney J, Stirzaker C, Qu W, Song JZ, Statham AL, Patterson KI, Horvath LG, Tabor B, Coolen MW, Hulf T, Kench JG, Henshall SM, Pe Benito R, Haynes AM, Mayor R, Peinado MA, Sutherland RL, Clark SJ (2011) Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers. Cancer Epidemiol Biomarkers Prev 20:148–159. https://doi.org/10.1158/1055-9965.Epi-10-0719
doi: 10.1158/1055-9965.Epi-10-0719
pubmed: 21098650
Di Loreto C, Reis FM, Cataldi P, Zuiani C, Luisi S, Beltrami CA, Petraglia F (1999) Human mammary gland and breast carcinoma contain immunoreactive inhibin/activin subunits: evidence for a secretion into cystic fluid. Eur J Endocrinol 141:190–194. https://doi.org/10.1530/eje.0.1410190
doi: 10.1530/eje.0.1410190
pubmed: 10427163
Duan R, Du W, Guo W (2020) EZH2: a novel target for cancer treatment. J Hematol Oncol 13:104. https://doi.org/10.1186/s13045-020-00937-8
doi: 10.1186/s13045-020-00937-8
pubmed: 32723346
pmcid: 7385862
Eriksson N, Benton GM, Do CB, Kiefer AK, Mountain JL, Hinds DA, Francke U, Tung JY (2012) Genetic variants associated with breast size also influence breast cancer risk. BMC Med Genet 13:53. https://doi.org/10.1186/1471-2350-13-53
doi: 10.1186/1471-2350-13-53
pubmed: 22747683
pmcid: 3483246
Evans ET, Horst B, Arend RC, Mythreye K (2023) Evolving roles of activins and inhibins in ovarian cancer pathophysiology. Am J Physiol Cell Physiol 324:C428–c437. https://doi.org/10.1152/ajpcell.00178.2022
doi: 10.1152/ajpcell.00178.2022
pubmed: 36622068
pmcid: 9902228
Ganz T (2013) Systemic iron homeostasis. Physiol Rev 93:1721–1741. https://doi.org/10.1152/physrev.00008.2013
doi: 10.1152/physrev.00008.2013
pubmed: 24137020
Geh E, Meng Q, Mongan M, Wang J, Takatori A, Zheng Y, Puga A, Lang RA, Xia Y (2011) Mitogen-activated protein kinase kinase kinase 1 (MAP3K1) integrates developmental signals for eyelid closure. Proc Natl Acad Sci U S A 108:17349–17354. https://doi.org/10.1073/pnas.1102297108
doi: 10.1073/pnas.1102297108
pubmed: 21969564
pmcid: 3198332
Gherardi S, Ripoche D, Mikaelian I, Chanal M, Teinturier R, Goehrig D, Cordier-Bussat M, Zhang CX, Hennino A, Bertolino P (2017) Menin regulates Inhbb expression through an Akt/Ezh2-mediated H3K27 histone modification. Biochim Biophys Acta Gene Regul Mech 1860:427–437. https://doi.org/10.1016/j.bbagrm.2017.02.003
doi: 10.1016/j.bbagrm.2017.02.003
pubmed: 28215965
Gingelmaier A, Gutsche S, Mylonas I, Shabani N, Kuhn C, Kunze S, Jeschke U, Friese K (2007) Expression of HPV, steroid receptors (ERalpha, ERbeta, PR-A and PR-B) and inhibin/activin subunits (alpha, betaA and betaB) in adenosquamous endometrial carcinoma. Anticancer Res 27:2011–2017
pubmed: 17649814
Grafe I, Alexander S, Peterson JR, Snider TN, Levi B, Lee B, Mishina Y (2018) TGF-β Family Signaling in Mesenchymal differentiation. Cold Spring Harb Perspect Biol 10. https://doi.org/10.1101/cshperspect.a022202
Gray PC, Vale W (2012) Cripto/GRP78 modulation of the TGF-β pathway in development and oncogenesis. FEBS Lett 586:1836–1845. https://doi.org/10.1016/j.febslet.2012.01.051
doi: 10.1016/j.febslet.2012.01.051
pubmed: 22306319
pmcid: 3723343
Gray PC, Bilezikjian LM, Vale W (2001) Antagonism of activin by inhibin and inhibin receptors: a functional role for betaglycan-glycan. Mol Cell Endocrinol 180:47–53. https://doi.org/10.1016/s0303-7207(01)00515-9
doi: 10.1016/s0303-7207(01)00515-9
pubmed: 11451571
Gray PC, Harrison CA, Vale W (2003) Cripto forms a complex with activin and type II activin receptors and can block activin signaling. Proc Natl Acad Sci U S A 100:5193–5198. https://doi.org/10.1073/pnas.0531290100
doi: 10.1073/pnas.0531290100
pubmed: 12682303
pmcid: 154321
Gutierrez A, Demond H, Brebi P, Ili CG (2021) Novel methylation biomarkers for Colorectal Cancer Prognosis. https://doi.org/10.3390/biom11111722 . Biomolecules 11
Hata A, Chen YG (2016) TGF-β signaling from receptors to Smads. Cold Spring Harb Perspect Biol 8. https://doi.org/10.1101/cshperspect.a022061
Hedger MP, Winnall WR, Phillips DJ, de Kretser DM (2011) The regulation and functions of activin and follistatin in inflammation and immunity. Vitam Horm 85:255–297. https://doi.org/10.1016/b978-0-12-385961-7.00013-5
doi: 10.1016/b978-0-12-385961-7.00013-5
pubmed: 21353885
Irvin SR, Weiderpass E, Stanczyk FZ, Brinton LA, Trabert B, Langseth H, Wentzensen N (2020) Association of anti-mullerian hormone, follicle-stimulating hormone, and Inhibin B with Risk of Ovarian Cancer in the Janus Serum Bank. Cancer Epidemiol Biomarkers Prev 29:636–642. https://doi.org/10.1158/1055-9965.Epi-19-0675
doi: 10.1158/1055-9965.Epi-19-0675
pubmed: 31932414
pmcid: 7060092
Jiang L, Hermeking H (2017) miR-34a and miR-34b/c suppress intestinal tumorigenesis. Cancer Res 77:2746–2758. https://doi.org/10.1158/0008-5472.Can-16-2183
doi: 10.1158/0008-5472.Can-16-2183
pubmed: 28363996
Jückstock J, Brüning A, Blankenstein T, Kunze S, Shabani N, Bergauer F, Mylonas I (2010) Immunolabeling of the inhibin-βA and -βB subunit in normal and malignant human cervical tissue and cervical cancer cell lines. Int J Gynecol Cancer 20:1117–1124. https://doi.org/10.1111/IGC.0b013e3181ef10aa
doi: 10.1111/IGC.0b013e3181ef10aa
pubmed: 21475087
Jung B, Staudacher JJ, Beauchamp D (2017) Transforming growth factor β Superfamily Signaling in Development of Colorectal Cancer. Gastroenterology 152:36–52. https://doi.org/10.1053/j.gastro.2016.10.015
doi: 10.1053/j.gastro.2016.10.015
pubmed: 27773809
Kalli M, Mpekris F, Wong CK, Panagi M, Ozturk S, Thiagalingam S, Stylianopoulos T, Papageorgis P (2019) Activin A Signaling regulates IL13Rα2 expression to promote breast Cancer metastasis. Front Oncol 9:32. https://doi.org/10.3389/fonc.2019.00032
doi: 10.3389/fonc.2019.00032
pubmed: 30805303
pmcid: 6370707
Kanamori Y, Sugiyama M, Hashimoto O, Murakami M, Matsui T, Funaba M (2016) Regulation of hepcidin expression by inflammation-induced activin B. Sci Rep 6:38702. https://doi.org/10.1038/srep38702
doi: 10.1038/srep38702
pubmed: 27922109
pmcid: 5138601
Karpinski P, Ramsey D, Grzebieniak Z, Sasiadek MM, Blin N (2008) The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer. Mol Cancer Res 6:585–591. https://doi.org/10.1158/1541-7786.Mcr-07-2158
doi: 10.1158/1541-7786.Mcr-07-2158
pubmed: 18403637
Kelber JA, Shani G, Booker EC, Vale WW, Gray PC (2008) Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal. J Biol Chem 283:4490–4500. https://doi.org/10.1074/jbc.M704960200
doi: 10.1074/jbc.M704960200
pubmed: 18089557
Kelber JA, Panopoulos AD, Shani G, Booker EC, Belmonte JC, Vale WW, Gray PC (2009) Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways. Oncogene 28:2324–2336. https://doi.org/10.1038/onc.2009.97
doi: 10.1038/onc.2009.97
pubmed: 19421146
pmcid: 2749668
Khalil AM, Dotimas H, Kahn J, Lamerdin JE, Hayes DB, Gupta P, Franti M (2016) Differential binding activity of TGF-β family proteins to select TGF-β receptors. J Pharmacol Exp Ther 358:423–430. https://doi.org/10.1124/jpet.116.232322
doi: 10.1124/jpet.116.232322
pubmed: 27340210
Kita A, Kasamatsu A, Nakashima D, Endo-Sakamoto Y, Ishida S, Shimizu T, Kimura Y, Miyamoto I, Yoshimura S, Shiiba M, Tanzawa H, Uzawa K (2017) Activin B regulates adhesion, invasiveness, and migratory activities in oral Cancer: a potential biomarker for Metastasis. J Cancer 8:2033–2041. https://doi.org/10.7150/jca.18714
doi: 10.7150/jca.18714
pubmed: 28819404
pmcid: 5559965
Knight PG, Glister C (2001) Potential local regulatory functions of inhibins, activins and follistatin in the ovary. Reproduction 121:503–512. https://doi.org/10.1530/rep.0.1210503
doi: 10.1530/rep.0.1210503
pubmed: 11277869
Lachat C, Bruyère D, Etcheverry A, Aubry M, Mosser J, Warda W, Herfs M, Hendrick E, Ferrand C, Borg C, Delage-Mourroux R, Feugeas JP, Guittaut M, Hervouet E, Peixoto P (2020) EZH2 and KDM6B expressions are Associated with specific epigenetic signatures during EMT in non small cell lung carcinomas. Cancers (Basel) 12. https://doi.org/10.3390/cancers12123649
Lebrun JJ, Vale WW (1997) Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation. Mol Cell Biol 17:1682–1691. https://doi.org/10.1128/mcb.17.3.1682
doi: 10.1128/mcb.17.3.1682
pubmed: 9032295
pmcid: 231893
Lidbury BA, Kita B, Lewis DP, Hayward S, Ludlow H, Hedger MP, de Kretser DM (2017) Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study. J Transl Med 15:60. https://doi.org/10.1186/s12967-017-1161-4
doi: 10.1186/s12967-017-1161-4
pubmed: 28302133
pmcid: 5353946
Ling N, Ying SY, Ueno N, Shimasaki S, Esch F, Hotta M, Guillemin R (1986) Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin. Nature 321:779–782. https://doi.org/10.1038/321779a0
doi: 10.1038/321779a0
pubmed: 3086749
Long J, Zhang B, Signorello LB, Cai Q, Deming-Halverson S, Shrubsole MJ, Sanderson M, Dennis J, Michailidou K, Easton DF, Shu XO, Blot WJ, Zheng W (2013) Evaluating genome-wide association study-identified breast cancer risk variants in African-American women. PLoS ONE 8:e58350. https://doi.org/10.1371/journal.pone.0058350
doi: 10.1371/journal.pone.0058350
pubmed: 23593120
pmcid: 3620157
Loomans HA, Andl CD (2016) Activin receptor-like kinases: a diverse family playing an important role in cancer. Am J Cancer Res 6:2431–2447
pubmed: 27904762
pmcid: 5126264
Luckett KA, Cracchiolo JR, Krishnamoorthy GP, Leandro-Garcia LJ, Nagarajah J, Saqcena M, Lester R, Im SY, Zhao Z, Lowe SW, de Stanchina E, Sherman EJ, Ho AL, Leach SD, Knauf JA, Fagin JA (2021) Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers. Endocr Relat Cancer 28:391–402. https://doi.org/10.1530/erc-21-0017
doi: 10.1530/erc-21-0017
pubmed: 33890869
pmcid: 8183640
Machida H, Ogawa K, Funaba M, Mizutani T, Tsujimoto M (2000) mRNA expression of type I and type II receptors for activin, transforming growth factor-beta, and bone morphogenetic protein in the murine erythroleukemic cell line, F5-5.Fl. Eur J Endocrinol 143:705–710. https://doi.org/10.1530/eje.0.1430705
doi: 10.1530/eje.0.1430705
pubmed: 11078996
Magnusson B, Svensson PA, Carlsson LM, Sjöholm K (2010) Activin B inhibits lipolysis in 3T3-L1 adipocytes. Biochem Biophys Res Commun 395:373–376. https://doi.org/10.1016/j.bbrc.2010.04.022
doi: 10.1016/j.bbrc.2010.04.022
pubmed: 20382119
Makanji Y, Zhu J, Mishra R, Holmquist C, Wong WP, Schwartz NB, Mayo KE, Woodruff TK (2014) Inhibin at 90: from discovery to clinical application, a historical review. Endocr Rev 35:747–794. https://doi.org/10.1210/er.2014-1003
doi: 10.1210/er.2014-1003
pubmed: 25051334
pmcid: 4167436
Maldonado TS, Kadison AS, Crisera CA, Grau JB, Alkasab SL, Longaker MT, Gittes GK (2000) Ontogeny of activin B and follistatin in developing embryonic mouse pancreas: implications for lineage selection. J Gastrointest Surg 4:269–275. https://doi.org/10.1016/s1091-255x(00)80075-x
doi: 10.1016/s1091-255x(00)80075-x
pubmed: 10769089
Matsuo SE, Ebina KN, Kulcsar MA, Friguglietti CU, Kimura ET (2003) Activin betaB expression in rat experimental goiter and human thyroid tumors. Thyroid 13:239–247. https://doi.org/10.1089/105072503321582033
doi: 10.1089/105072503321582033
pubmed: 12729472
Mayor R, Casadomé L, Azuara D, Moreno V, Clark SJ, Capellà G, Peinado MA (2009) Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease. Br J Cancer 100:1534–1539. https://doi.org/10.1038/sj.bjc.6605045
doi: 10.1038/sj.bjc.6605045
pubmed: 19384295
pmcid: 2696749
McCullagh DR (1932) DUAL ENDOCRINE ACTIVITY OF THE TESTES. Science 76:19–20. https://doi.org/10.1126/science.76.1957.19
doi: 10.1126/science.76.1957.19
pubmed: 17815236
McPherson SJ, Thomas TZ, Wang H, Gurusinghe CJ, Risbridger GP (1997) Growth inhibitory response to activin A and B by human prostate tumour cell lines, LNCaP and DU145. J Endocrinol 154:535–545. https://doi.org/10.1677/joe.0.1540535
doi: 10.1677/joe.0.1540535
pubmed: 9379131
Mellor SL, Richards MG, Pedersen JS, Robertson DM, Risbridger GP (1998) Loss of the expression and localization of inhibin alpha-subunit in high grade prostate cancer. J Clin Endocrinol Metab 83:969–975. https://doi.org/10.1210/jcem.83.3.4640
doi: 10.1210/jcem.83.3.4640
pubmed: 9506758
Meng Q, Xia Y (2011) c-Jun, at the crossroad of the signaling network. Protein Cell 2:889–898. https://doi.org/10.1007/s13238-011-1113-3
doi: 10.1007/s13238-011-1113-3
pubmed: 22180088
pmcid: 4875184
Michael IP, Saghafinia S, Tichet M, Zangger N, Marinoni I, Perren A, Hanahan D (2019) ALK7 Signaling manifests a homeostatic tissue barrier that is abrogated during Tumorigenesis and metastasis. Dev Cell 49:409–424e406. https://doi.org/10.1016/j.devcel.2019.04.015
doi: 10.1016/j.devcel.2019.04.015
pubmed: 31063757
Miyazono K (2000) Positive and negative regulation of TGF-beta signaling. J Cell Sci 113(Pt 7):1101–1109
doi: 10.1242/jcs.113.7.1101
pubmed: 10704361
Mylonas I (2010) Inhibin-alpha, -betaA and -betab subunits in uterine non-endometrioid carcinomas: prognostic significance and clinical implications. Eur J Cancer 46:2485–2493. https://doi.org/10.1016/j.ejca.2010.06.001
doi: 10.1016/j.ejca.2010.06.001
pubmed: 20599374
Mylonas I (2011) Inhibin beta B: a useful tumor marker in uterine endometrioid adenocarcinomas? Histol Histopathol 26:1415–1422. https://doi.org/10.14670/hh-26.1415
doi: 10.14670/hh-26.1415
pubmed: 21938679
Mylonas I, Dian D (2011) Inhibin-α subunit in normal and malignant human cervical tissue and cervical cancer cell lines. Oncol Rep 26:887–891. https://doi.org/10.3892/or.2011.1379
doi: 10.3892/or.2011.1379
pubmed: 21743968
Mylonas I, Jeschke U, Wiest I, Hoeing A, Vogl J, Shabani N, Kuhn C, Schulze S, Kupka MS, Friese K (2004) Inhibin/activin subunits alpha, beta-A and beta-B are differentially expressed in normal human endometrium throughout the menstrual cycle. Histochem Cell Biol 122:461–471. https://doi.org/10.1007/s00418-004-0709-6
doi: 10.1007/s00418-004-0709-6
pubmed: 15480736
Mylonas I, Jeschke U, Shabani N, Kuhn C, Friese K, Gerber B (2005) Inhibin/activin subunits (inhibin-alpha, -betaA and -betab) are differentially expressed in human breast cancer and their metastasis. Oncol Rep 13:81–88
pubmed: 15583806
Mylonas I, Makovitzky J, Hoeing A, Richter DU, Vogl J, Schulze S, Jeschke U, Briese V, Friese K (2006) Inhibin/activin subunits beta-A (-betaA) and beta-B (-betaB) are differentially localised in normal, hyperplastic and malignant human endometrial tissue. Acta Histochem 108:1–11. https://doi.org/10.1016/j.acthis.2005.11.002
doi: 10.1016/j.acthis.2005.11.002
pubmed: 16423381
Mylonas I, Worbs S, Shabani N, Kuhn C, Kunze S, Schulze S, Dian D, Gingelmaier A, Schindlbeck C, Brüning A, Sommer H, Jeschke U, Friese K (2009) Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin/activin-alpha, -betaA and -betab subunits in 302 cases. Eur J Cancer 45:1304–1314. https://doi.org/10.1016/j.ejca.2009.01.008
doi: 10.1016/j.ejca.2009.01.008
pubmed: 19231155
Nairz M, Weiss G (2020) Iron in infection and immunity. Mol Aspects Med 75:100864. https://doi.org/10.1016/j.mam.2020.100864
doi: 10.1016/j.mam.2020.100864
pubmed: 32461004
Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH, Miyazono K, ten Dijke P (1997) TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. Embo j 16:5353–5362. https://doi.org/10.1093/emboj/16.17.5353
doi: 10.1093/emboj/16.17.5353
pubmed: 9311995
pmcid: 1170167
Nickel J, Ten Dijke P, Mueller TD (2018) TGF-β family co-receptor function and signaling. Acta Biochim Biophys Sin (Shanghai) 50:12–36. https://doi.org/10.1093/abbs/gmx126
doi: 10.1093/abbs/gmx126
pubmed: 29293886
Olsen OE, Hella H, Elsaadi S, Jacobi C, Martinez-Hackert E, Holien T (2020) Activins as dual specificity TGF-β family molecules: SMAD-Activation via activin- and BMP-Type 1 receptors. https://doi.org/10.3390/biom10040519 . Biomolecules 10
Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massagué J, Niehrs C (1999) Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature 401:480–485. https://doi.org/10.1038/46794
doi: 10.1038/46794
pubmed: 10519551
Pan C, Singh S, Sahasrabudhe DM, Chakkalakal JV, Krolewski JJ, Nastiuk KL (2016) TGFβ superfamily members mediate Androgen Deprivation Therapy-Induced obese frailty in male mice. Endocrinology 157:4461–4472. https://doi.org/10.1210/en.2016-1580
doi: 10.1210/en.2016-1580
pubmed: 27611336
pmcid: 5414572
Pickup MW, Owens P, Moses HL (2017) TGF-β, bone morphogenetic protein, and activin signaling and the Tumor Microenvironment. Cold Spring Harb Perspect Biol 9. https://doi.org/10.1101/cshperspect.a022285
Qian Z, Zhang G, Song G, Shi J, Gong L, Mou Y, Han Y (2017) Integrated analysis of genes associated with poor prognosis of patients with colorectal cancer liver metastasis. Oncotarget 8:25500–25512. https://doi.org/10.18632/oncotarget.16064
doi: 10.18632/oncotarget.16064
pubmed: 28424419
pmcid: 5421946
Reader KL, John-McHaffie S, Zellhuber-McMillan S, Jowett T, Mottershead DG, Cunliffe HE, Gold EJ (2022) Activin B and activin C have Opposing effects on prostate Cancer progression and cell growth. Cancers (Basel) 15. https://doi.org/10.3390/cancers15010147
Refaat B, El-Shemi AG, Mohamed AM, Kensara OA, Ahmad J, Idris S (2016) Activins and their related proteins in colon carcinogenesis: insights from early and advanced azoxymethane rat models of colon cancer. BMC Cancer 16:879. https://doi.org/10.1186/s12885-016-2914-9
doi: 10.1186/s12885-016-2914-9
pubmed: 27835986
pmcid: 5106801
Ripoche D, Charbord J, Hennino A, Teinturier R, Bonnavion R, Jaafar R, Goehrig D, Cordier-Bussat M, Ritvos O, Zhang CX, Andersson O, Bertolino P (2015) ActivinB is Induced in Insulinoma to promote Tumor plasticity through a β-Cell-Induced dedifferentiation. Mol Cell Biol 36:756–764. https://doi.org/10.1128/mcb.00930-15
doi: 10.1128/mcb.00930-15
pubmed: 26711255
Roberts VJ, Barth S, el-Roeiy A, Yen SS (1993) Expression of inhibin/activin subunits and follistatin messenger ribonucleic acids and proteins in ovarian follicles and the corpus luteum during the human menstrual cycle. J Clin Endocrinol Metab 77:1402–1410. https://doi.org/10.1210/jcem.77.5.8077341
doi: 10.1210/jcem.77.5.8077341
pubmed: 8077341
Salmenkivi K, Arola J, Voutilainen R, Ilvesmäki V, Haglund C, Kahri AI, Heikkilä P, Liu J (2001) Inhibin/activin betab-subunit expression in pheochromocytomas favors benign diagnosis. J Clin Endocrinol Metab 86:2231–2235. https://doi.org/10.1210/jcem.86.5.7446
doi: 10.1210/jcem.86.5.7446
pubmed: 11344232
Sangkop F, Singh G, Rodrigues E, Gold E, Bahn A (2016) Uric acid: a modulator of prostate cells and activin sensitivity. Mol Cell Biochem 414:187–199. https://doi.org/10.1007/s11010-016-2671-8
doi: 10.1007/s11010-016-2671-8
pubmed: 26910779
Seachrist DD, Keri RA (2019) The activin Social Network: activin, Inhibin, and follistatin in breast development and Cancer. Endocrinology 160:1097–1110. https://doi.org/10.1210/en.2019-00015
doi: 10.1210/en.2019-00015
pubmed: 30874767
pmcid: 6475112
Takatori A, Geh E, Chen L, Zhang L, Meller J, Xia Y (2008) Differential transmission of MEKK1 morphogenetic signals by JNK1 and JNK2. Development 135:23–32. https://doi.org/10.1242/dev.007120
doi: 10.1242/dev.007120
pubmed: 18032450
Tang P, Wang X, Zhang M, Huang S, Lin C, Yan F, Deng Y, Zhang L, Zhang L (2019) Activin B stimulates mouse Vibrissae Growth and regulates cell proliferation and cell cycle progression of Hair Matrix cells through ERK Signaling. Int J Mol Sci 20. https://doi.org/10.3390/ijms20040853
Thompson TB, Cook RW, Chapman SC, Jardetzky TS, Woodruff TK (2004) Beta A versus beta B: is it merely a matter of expression? Mol Cell Endocrinol 225:9–17. https://doi.org/10.1016/j.mce.2004.02.007
doi: 10.1016/j.mce.2004.02.007
pubmed: 15451562
Tsuchida K, Arai KY, Kuramoto Y, Yamakawa N, Hasegawa Y, Sugino H (2000) Identification and characterization of a novel follistatin-like protein as a binding protein for the TGF-beta family. J Biol Chem 275:40788–40796. https://doi.org/10.1074/jbc.M006114200
doi: 10.1074/jbc.M006114200
pubmed: 11010968
Tsuchida K, Nakatani M, Yamakawa N, Hashimoto O, Hasegawa Y, Sugino H (2004) Activin isoforms signal through type I receptor serine/threonine kinase ALK7. Mol Cell Endocrinol 220:59–65. https://doi.org/10.1016/j.mce.2004.03.009
doi: 10.1016/j.mce.2004.03.009
pubmed: 15196700
Tzavlaki K, Moustakas A (2020) TGF-β signaling. https://doi.org/10.3390/biom10030487 . Biomolecules 10
Vale W, Rivier J, Vaughan J, McClintock R, Corrigan A, Woo W, Karr D, Spiess J (1986) Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 321:776–779. https://doi.org/10.1038/321776a0
doi: 10.1038/321776a0
pubmed: 3012369
Valer JA, Sánchez-de-Diego C, Pimenta-Lopes C, Rosa JL, Ventura F (2019) ACVR1 function in Health and Disease. Cells 8. https://doi.org/10.3390/cells8111366
van Schaik RH, Wierikx CD, Timmerman MA, Oomen MH, van Weerden WM, van der Kwast TH, van Steenbrugge GJ, de Jong FH (2000) Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues. Br J Cancer 82:112–117. https://doi.org/10.1054/bjoc.1999.0886
doi: 10.1054/bjoc.1999.0886
pubmed: 10638976
Vannuccini S, Clemenza S, Rossi M, Petraglia F (2022) Hormonal treatments for endometriosis: the endocrine background. Rev Endocr Metab Disord 23:333–355. https://doi.org/10.1007/s11154-021-09666-w
doi: 10.1007/s11154-021-09666-w
pubmed: 34405378
Vogl J, Höing A, Schulze S, Kuhn C, Wiest I, Shabani N, Jeschke U, Mylonas I, Friese K (2007) Expression of inhibins in the endometrial carcinoma cell line RL-95-2 after stimulation with cortisol and estradiol. Anticancer Res 27:1989–1993
pubmed: 17649810
Wacker I, Behrens J (2014) Activin B antagonizes RhoA signaling to stimulate mesenchymal morphology and invasiveness of clear cell renal cell carcinomas. PLoS ONE 9:e111276. https://doi.org/10.1371/journal.pone.0111276
doi: 10.1371/journal.pone.0111276
pubmed: 25343250
pmcid: 4208853
Wacker I, Sachs M, Knaup K, Wiesener M, Weiske J, Huber O, Akçetin Z, Behrens J (2009) Key role for activin B in cellular transformation after loss of the Von Hippel-Lindau tumor suppressor. Mol Cell Biol 29:1707–1718. https://doi.org/10.1128/mcb.01184-07
doi: 10.1128/mcb.01184-07
pubmed: 19158274
pmcid: 2655617
Walentowicz P, Krintus M, Sadlecki P, Grabiec M, Mankowska-Cyl A, Sokup A, Walentowicz-Sadlecka M (2014) Serum inhibin A and inhibin B levels in epithelial ovarian cancer patients. PLoS ONE 9:e90575. https://doi.org/10.1371/journal.pone.0090575
doi: 10.1371/journal.pone.0090575
pubmed: 24599287
pmcid: 3944095
Walton KL, Makanji Y, Wilce MC, Chan KL, Robertson DM, Harrison CA (2009) A common biosynthetic pathway governs the dimerization and secretion of inhibin and related transforming growth factor beta (TGFbeta) ligands. J Biol Chem 284:9311–9320. https://doi.org/10.1074/jbc.M808763200
doi: 10.1074/jbc.M808763200
pubmed: 19193648
pmcid: 2666583
Walton KL, Makanji Y, Harrison CA (2012) New insights into the mechanisms of activin action and inhibition. Mol Cell Endocrinol 359:2–12. https://doi.org/10.1016/j.mce.2011.06.030
doi: 10.1016/j.mce.2011.06.030
pubmed: 21763751
Wang X, Fischer G, Hyvönen M (2016) Structure and activation of pro-activin A. Nat Commun 7:12052. https://doi.org/10.1038/ncomms12052
doi: 10.1038/ncomms12052
pubmed: 27373274
pmcid: 4932183
Wang X, Tang P, Guo F, Zhang M, Chen Y, Yan Y, Tian Z, Xu P, Zhang L, Zhang L, Zhang L (2017) RhoA regulates activin B-induced stress fiber formation and migration of bone marrow-derived mesenchymal stromal cell through distinct signaling. Biochim Biophys Acta Gen Subj 1861:3011–3018. https://doi.org/10.1016/j.bbagen.2016.09.027
doi: 10.1016/j.bbagen.2016.09.027
pubmed: 27693126
Wang X, Tang P, Guo F, Zhang M, Yan Y, Huang M, Chen Y, Zhang L, Zhang L (2019) mDia1 and Cdc42 regulate activin B-Induced Migration of Bone Marrow-derived mesenchymal stromal cells. Stem Cells 37:150–162. https://doi.org/10.1002/stem.2924
doi: 10.1002/stem.2924
pubmed: 30358011
Watson SK, Woolcock BW, Fee JN, Bainbridge TC, Webber D, Kinahan TJ, Lam WL, Vielkind JR (2009) Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization. Prostate 69:961–975. https://doi.org/10.1002/pros.20949
doi: 10.1002/pros.20949
pubmed: 19267368
Wijayarathna R, de Kretser DM (2016) Activins in reproductive biology and beyond. Hum Reprod Update 22:342–357. https://doi.org/10.1093/humupd/dmv058
doi: 10.1093/humupd/dmv058
pubmed: 26884470
Wijayarathna R, Hedger MP (2019) Activins, follistatin and immunoregulation in the epididymis. Andrology 7:703–711. https://doi.org/10.1111/andr.12682
doi: 10.1111/andr.12682
pubmed: 31322318
Worbs S, Shabani N, Mayr D, Gingelmaier A, Makrigiannakis A, Kuhn C, Jeschke U, Kupka MS, Friese K, Mylonas I (2007) Expression of the inhibin/activin subunits (-alpha, -betaA and -betab) in normal and carcinogenic endometrial tissue: possible immunohistochemical differentiation markers. Oncol Rep 17:97–104
pubmed: 17143484
Wu B, Zhang S, Guo Z, Bi Y, Zhou M, Li P, Seyedsadr M, Xu X, Li JL, Markovic-Plese S, Wan YY (2021) The TGF-β superfamily cytokine Activin-A is induced during autoimmune neuroinflammation and drives pathogenic Th17 cell differentiation. Immunity 54:308–323e306. https://doi.org/10.1016/j.immuni.2020.12.010
doi: 10.1016/j.immuni.2020.12.010
pubmed: 33421362
pmcid: 7878438
Xin C, Lai Y, Ji L, Wang Y, Li S, Hao L, Zhang W, Meng R, Xu J, Hong Y, Lou Z (2022) A novel 9-gene signature for the prediction of postoperative recurrence in stage II/III colorectal cancer. Front Genet 13:1097234. https://doi.org/10.3389/fgene.2022.1097234
doi: 10.3389/fgene.2022.1097234
pubmed: 36704343
Xiong S, Klausen C, Cheng JC, Zhu H, Leung PC (2015) Activin B induces human endometrial cancer cell adhesion, migration and invasion by up-regulating integrin β3 via SMAD2/3 signaling. Oncotarget 6:31659–31673. https://doi.org/10.18632/oncotarget.5229
doi: 10.18632/oncotarget.5229
pubmed: 26384307
pmcid: 4741631
Xiong S, Klausen C, Cheng JC, Leung PC (2016) Activin B promotes endometrial cancer cell migration by down-regulating E-cadherin via SMAD-independent MEK-ERK1/2-SNAIL signaling. Oncotarget 7:40060–40072. https://doi.org/10.18632/oncotarget.9483
doi: 10.18632/oncotarget.9483
pubmed: 27223076
pmcid: 5129992
Xu Z, Li Y, Cui Y, Guo Y (2020) Identifications of candidate genes significantly Associated with rectal Cancer by Integrated Bioinformatics Analysis. Technol Cancer Res Treat 19:1533033820973270. https://doi.org/10.1177/1533033820973270
doi: 10.1177/1533033820973270
pubmed: 33327880
pmcid: 7750891
Yadin D, Knaus P, Mueller TD (2016) Structural insights into BMP receptors: specificity, activation and inhibition. Cytokine Growth Factor Rev 27:13–34. https://doi.org/10.1016/j.cytogfr.2015.11.005
doi: 10.1016/j.cytogfr.2015.11.005
pubmed: 26690041
Yamashita K, Yamoto M, Shikone T, Minami S, Imai M, Nishimori K, Nakano R (1997) Production of inhibin A and inhibin B in human ovarian sex cord stromal tumors. Am J Obstet Gynecol 177:1450–1457. https://doi.org/10.1016/s0002-9378(97)70090-5
doi: 10.1016/s0002-9378(97)70090-5
pubmed: 9423750
Yamashita K, Yamoto M, Shikone T, Minami S, Nakano R (1999) Immunohistochemical localization of inhibin and activin subunits in human epithelial ovarian tumors. Am J Obstet Gynecol 180:316–322. https://doi.org/10.1016/s0002-9378(99)70206-1
doi: 10.1016/s0002-9378(99)70206-1
pubmed: 9988793
Yang X, Jia Q, Zou Z, Liu X, Li X, Chen H, Ma H, Chen L (2023) INHBB promotes tumor aggressiveness and stemness of glioblastoma via activating EGFR signaling. Pathol Res Pract 245:154460. https://doi.org/10.1016/j.prp.2023.154460
doi: 10.1016/j.prp.2023.154460
pubmed: 37116368
Yin Y, Yang S, Huang Z, Yang Z, Zhang C, He Y (2024) RNA methylation-related genes INHBB and SOWAHA are associated with MSI status in colorectal cancer patients and may serve as prognostic markers for predicting immunotherapy efficacy. https://doi.org/10.1093/carcin/bgae004 . Carcinogenesis
Ying SY (1987) Inhibins and activins: chemical properties and biological activity. Proc Soc Exp Biol Med 186:253–264. https://doi.org/10.3181/00379727-186-42611a
doi: 10.3181/00379727-186-42611a
pubmed: 3122219
Ying SY (1988) Inhibins, activins, and follistatins: gonadal proteins modulating the secretion of follicle-stimulating hormone. Endocr Rev 9:267–293. https://doi.org/10.1210/edrv-9-2-267
doi: 10.1210/edrv-9-2-267
pubmed: 3136011
Yu W, He G, Zhang W, Ye Z, Zhong Z, Huang S (2022) INHBB is a novel prognostic biomarker and correlated with immune infiltrates in gastric cancer. Front Genet 13:933862. https://doi.org/10.3389/fgene.2022.933862
doi: 10.3389/fgene.2022.933862
pubmed: 36118865
pmcid: 9478859
Yuan J, Xie A, Cao Q, Li X, Chen J (2020) INHBB is a Novel Prognostic Biomarker Associated with Cancer-promoting pathways in Colorectal Cancer. Biomed Res Int 2020:6909672. https://doi.org/10.1155/2020/6909672
doi: 10.1155/2020/6909672
pubmed: 33083477
pmcid: 7563060
Zeng F, Xu G, Zhou T, Yang C, Wang X, Peng C, Zhou H (2012) Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression. Med Oncol 29:2519–2526. https://doi.org/10.1007/s12032-011-0114-7
doi: 10.1007/s12032-011-0114-7
pubmed: 22086737
Zessner-Spitzenberg J, Thomas AL, Krett NL, Jung B (2019) TGFβ and activin A in the tumor microenvironment in colorectal cancer. Gene Rep 17. https://doi.org/10.1016/j.genrep.2019.100501
Zhang L, Deng M, Parthasarathy R, Wang L, Mongan M, Molkentin JD, Zheng Y, Xia Y (2005) MEKK1 transduces activin signals in keratinocytes to induce actin stress fiber formation and migration. Mol Cell Biol 25:60–65. https://doi.org/10.1128/mcb.25.1.60-65.2005
doi: 10.1128/mcb.25.1.60-65.2005
pubmed: 15601830
pmcid: 538759
Zhang M, Liu NY, Wang XE, Chen YH, Li QL, Lu KR, Sun L, Jia Q, Zhang L, Zhang L (2011) Activin B promotes epithelial wound healing in vivo through RhoA-JNK signaling pathway. PLoS ONE 6:e25143. https://doi.org/10.1371/journal.pone.0025143
doi: 10.1371/journal.pone.0025143
pubmed: 21949871
pmcid: 3176320
Zhang M, Sun L, Wang X, Chen S, Kong Y, Liu N, Chen Y, Jia Q, Zhang L, Zhang L (2014) Activin B promotes BMSC-Mediated cutaneous Wound Healing by regulating Cell Migration via the JNK-ERK Signaling Pathway. Cell Transpl 23:1061–1073. https://doi.org/10.3727/096368913x666999
doi: 10.3727/096368913x666999
Zhang Y, Wang S, Liu S, Li C, Wang J (2015) Role of Smad signaling in kidney disease. Int Urol Nephrol 47:1965–1975. https://doi.org/10.1007/s11255-015-1115-9
doi: 10.1007/s11255-015-1115-9
pubmed: 26433882
Zhang L, Xu P, Wang X, Zhang M, Yan Y, Chen Y, Zhang L, Zhang L (2017) Activin B regulates adipose-derived mesenchymal stem cells to promote skin wound healing via activation of the MAPK signaling pathway. Int J Biochem Cell Biol 87:69–76. https://doi.org/10.1016/j.biocel.2017.04.004
doi: 10.1016/j.biocel.2017.04.004
pubmed: 28396222
Zhong X, Pons M, Poirier C, Jiang Y, Liu J, Sandusky GE, Shahda S, Nakeeb A, Schmidt CM, House MG, Ceppa EP, Zyromski NJ, Liu Y, Jiang G, Couch ME, Koniaris LG, Zimmers TA (2019) The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. J Cachexia Sarcopenia Muscle 10:1083–1101. https://doi.org/10.1002/jcsm.12461
doi: 10.1002/jcsm.12461
pubmed: 31286691
pmcid: 6818463
Zou G, Ren B, Liu Y, Fu Y, Chen P, Li X, Luo S, He J, Gao G, Zeng Z, Xiong W, Li G, Huang Y, Xu K, Zhang W (2018) Inhibin B suppresses anoikis resistance and migration through the transforming growth factor-β signaling pathway in nasopharyngeal carcinoma. Cancer Sci 109:3416–3427. https://doi.org/10.1111/cas.13780
doi: 10.1111/cas.13780
pubmed: 30151927
pmcid: 6215878
Zou ML, Chen ZH, Teng YY, Liu SY, Jia Y, Zhang KW, Sun ZL, Wu JJ, Yuan ZD, Feng Y, Li X, Xu RS, Yuan FL (2021) The smad dependent TGF-β and BMP signaling pathway in bone remodeling and therapies. Front Mol Biosci 8:593310. https://doi.org/10.3389/fmolb.2021.593310
doi: 10.3389/fmolb.2021.593310
pubmed: 34026818
pmcid: 8131681